secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-039035
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q2 product revenue $46.7M; Auvelity sales $27.6M, up 76% sequentially
----------------------------------------------------------------------------

- Total product revenue $46.7M vs $8.8M in Q2 2022 (Auvelity $27.6M, Sunosi $19.1M).
- Net loss $67.2M ($1.54/share) vs $41.4M loss in prior year; cash $437.1M at June 30, 2023.
- Expanding Auvelity sales force from 162 to 260 reps to reach 44,000 physicians.
- Initiated FOCUS Phase 3 trial of solriamfetol in ADHD; plans Phase 3 trials in binge eating (Q4 2023) and shift work disorder (Q1 2024).
- Anticipates AXS-12 narcolepsy Phase 3 topline in Q4 2023 and AXS-05 Alzheimer's agitation data in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023039035/0000950170-23-039035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023039035/axsm-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer